Frist Cressey Ventures
Frist Cressey Ventures identifies itself as a healthcare venture capital firm with locations in Nashville and New York. Its stated focus is early-stage healthcare companies using technology and tech-enabled services, including AI-native business models, to advance care delivery, outcomes, affordability, and access.
What stands out about Frist Cressey Ventures
Frist Cressey Ventures publicly describes an early-stage healthcare venture strategy centered on technology and tech-enabled services. The firm states that it provides capital, healthcare-industry connections, leadership and CEO support, talent assistance, and strategic value creation.[1][2][3][4]
What does Frist Cressey Ventures invest in?
Frist Cressey Ventures identifies itself as a venture capital firm on a mission to transform healthcare and improve lives, with locations in Nashville and New York.
FCV states that it partners with founders seeking to transform healthcare and provides support beyond capital, including leadership support and strategic value creation.[1][3]
FCV focuses on early-stage healthcare companies transforming care delivery through technology and tech-enabled services, including AI-native business models.
The firm describes its approach as providing capital alongside guidance, healthcare-industry connections, leadership support, CEO advising, talent access, and strategic value creation.[2][3][4]
Owners comparing capital alternatives can review Auxo’s capital advisory services, valuation services, and full-versus-partial sale framework.
Published criteria: FCV announced that it closed an oversubscribed $425 million Fund IV on February 18, 2026, bringing total assets under management to nearly $1 billion. It states that it invests in early-stage startups building technology or tech-enabled services that advance quality of care, system integration, patient outcomes, affordability, and access.[4]
What should a business owner evaluate before taking capital from Frist Cressey Ventures?
Owners and founders evaluating FCV should assess whether the company’s stage, healthcare focus, technology or tech-enabled-service model, and care-delivery objectives align with FCV’s stated investment criteria.
FCV publicly describes support involving capital, healthcare-industry connections, leadership evaluation and advising, talent assistance, and strategic value creation. An owner should clarify how those resources would apply to the company, along with check size, ownership expectations, governance rights, follow-on capacity, dilution, and investment or exit expectations. FCV’s Strategy page does not publish a universal investment check-size range, ownership target, or expected investment holding period, and its Partnerships page does not publish governance rights or complete transaction terms for listed companies.[2][3][4]
What stages and check sizes does the current fund target
Does FCV lead or participate, and what follow-on reserves are available
What investment criteria does Frist Cressey Ventures publicly describe?
FCV states that it invests in early-stage startups building technology or tech-enabled services to advance quality of care, system integration, patient outcomes, affordability, and access.
Its publicly listed partnerships include companies in healthcare delivery, digital health, healthcare software, clinical data, behavioral health, oncology, primary care, and related healthcare services.[2][4]
The stated criteria emphasize early-stage healthcare companies whose technology or tech-enabled services advance care quality, system integration, patient outcomes, affordability, or access.
FCV’s Strategy page does not publish a universal investment check-size range, ownership target, or valuation range.[3][4]
FCV publicly lists locations in Nashville and New York. Its strategic partners are described as providing healthcare to more than 50% of the U.S. population.
FCV’s Strategy page does not state a geographic investment mandate or restriction.[1][3][4]
FCV’s official Partnerships page lists active and past partnerships including Ambience Healthcare, Chamber Cardio, Carta Healthcare, CodaMetrix, Main Street Health, Monogram Health, OneOncology, Oshi Health, Praia Health, Qualified Health, Thyme Care, Vim, and Visana Health.
FCV’s Partnerships page identifies portfolio companies and describes FCV’s support, but does not publish FCV’s individual investment amount, ownership percentage, governance rights, or complete transaction terms for the listed companies.[2]
FCV’s official homepage identifies Chamber Cardio’s $60 million Series A funding announcement dated August 18, 2026, and Thyme Care’s $125+ million Series E announcement dated September 2, 2026.
FCV’s official newsroom identifies One to One Health’s $12 million investment announcement dated January 21, 2026.
On February 18, 2026, FCV announced that it had closed an oversubscribed $425 million Fund IV, bringing total assets under management to nearly $1 billion.[1][4][5]
What is not clear from Frist Cressey Ventures's public materials?
FCV’s Strategy page does not publish a universal investment check-size range, ownership target, valuation range, or expected investment holding period.
FCV’s Strategy page does not state a geographic investment mandate or restriction.
FCV’s Partnerships page does not publish FCV’s individual investment amount, ownership percentage, governance rights, or complete transaction terms for the listed companies.[2][3]
The SEC Investment Adviser Public Disclosure record for Frist Cressey Ventures Management, LLC states that the entity files reports as an Exempt Reporting Adviser and shows SEC ERA status as active effective January 30, 2019. The record shows the entity as not currently registered.
The SEC record concerns Frist Cressey Ventures Management, LLC and does not establish the regulatory status of every Frist Cressey Ventures fund or affiliate.[6]
Questions to ask before taking capital from Frist Cressey Ventures
What stages and check sizes does the current fund target?
What ownership or dilution range is typical?
Does FCV lead or participate, and what follow-on reserves are available?
What board, observer, information, or protective rights are normally requested?
Which healthcare-system or strategic-partner relationships may apply to this company?
How does FCV support recruiting, leadership, regulatory strategy, payer or provider introductions, and commercialization?
What is the expected investment horizon and approach to follow-on financings or exits?
Which FCV legal entity and fund would make the investment, and what regulatory, reporting, and fee arrangements apply?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Investment strategy
- Industry / market focus
- Transaction / portfolio evidence
- SEC investment adviser record
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.